Feasibility Study of Short-Course Pelvic Radiation with Carboplatin and Paclitaxel Chemotherapy in Stage III Endometrial Cancer Subtypes

What this Trial Is About

Researchers are evaluating whether a shorter radiation therapy schedule combined with chemotherapy is practical for people with stage III endometrial cancer. This early phase 1 study focuses on delivering radiation over one week instead of the usual five weeks, aiming to see if most participants can complete the treatment as planned. The study is sponsored by Memorial Sloan Kettering Cancer Center and includes patients with specific subtypes of endometrial carcinoma. Participants receive chemotherapy with carboplatin and paclitaxel every 21 days for up to six cycles. Radiation therapy using intensity-modulated radiation therapy IMRT is given after cycles 1 to 4, targeting the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy over five daily treatments. The study assesses the feasibility of integrating this short-course radiation with chemotherapy in treating stage III endometrial cancer. During the study, participants undergo regular evaluations including lab tests to ensure adequate organ function and monitor neurologic status. Researchers will measure how many participants can complete the combined treatment over up to three years. Safety and treatment feasibility are closely monitored, with participants followed for outcomes related to treatment completion and side effects throughout the study period.

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer